- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00446888
Effects of Nutritional Supplementation (Product 4808) on Acute Skeletal Muscle Protein Synthesis in Cancer Patients
Přehled studie
Postavení
Podmínky
Detailní popis
Muscle protein is generally diminished in cancer patients, with an effect on outcome. Research has shown that recurrence in treated patients is directly related to the extent of muscle loss. The effects of nutritional supplements; however, is still controversial. Anorexia due to metabolic changes in cancer patients can lead to reduced food intake and supplementation orally has often failed to show weight gain in these patients. These observations have led to the conclusion that even though food intake should be increased in order to gain lean body mass, this is difficult to achieve unless specific metabolic abnormalities are targeted.
This study is a comparison of two supplements on muscle protein synthesis. Approximately 40 patients with radiographic evidence of cancer, ages 40 and older will be enrolled.
Participation will require a screening procedure, including a history of medical problems and a physical exam, which may include blood testing for HIV or hepatitis as well as possibly for various basic diagnostic parameters. There may also be a urine-based drug screen or pregnancy test (if female). Participants should be in general good health and not have a variety of exclusion criteria.
There will be three days of diet stabilization, during which all meals will come from the Reynolds Institute of Aging. If subjects cannot comply with the diet, dietary recording will be substituted. Following these three days, there will be one day of main study activities. There will be catheters placed in both arms and blood samples will be taken from one of these. Stable amino acid isotopes will be infused into the bloodstream through the other. There will be three muscle biopsies taken from the thigh muscle throughout the day. Two doses of a nutritional supplements will be consumed 20 minutes apart during the main study day.
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Arkansas
-
Little Rock, Arkansas, Spojené státy, 72205
- University of Arkansas for Medical Sciences
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- radiographic evidence of Cancer
- Ages 40 and older
- Ability to sign Informed Consent
Exclusion Criteria:
- Patient received anti-cancer therapy or surgery less than 4 weeks prior to the experiment
- Body weight loss of more than 10% in past three months
- Body Mass Index less than 20kg/m2 or greater than 30 kg/m2
- Any documented autoimmune disease
- Peripheral vascular disease
- Hgb less than 9.0g/dL
- PT with INR greater than 1.5
- PTT greater than 40 seconds
- Platelet count less than 100,000
- Uncontrolled hypertension
- Currently using insulin to control high blood sugar
- Untreated metabolic diseases including liver or renal disease
- Currently in muscle strengthening program
- Use of supplements enriched with branched-chain amino acids
- History of hypo- or hyper-coagulation disorders, including patients taking Coumadin or history of deep venous thrombosis or pulmonary embolism at any point in their lifetime
- Currently taking aspirin and cannot stop for 7 days
- Presence of acute illness or metabolically unstable chronic illness
- Unstable heart disease requiring therapy or recent myocardial infarction (less than 1 year)
- Current alcohol or drug abuse
- Pregnancy or lactation (pre-menopausal women)
- Allergy/intolerance to any of the ingredients of the study products
- Any other condition deemed by the Principal Investigator and the study physician as exclusion or that interferes with proper study conduct or safety of the patient
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Diagnostický
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Aktivní komparátor: 1
these subjects will get a standard protein supplement "milkshake" during thei study.
|
Subjects will eat prepared meals for 3 days prior to their study; or they will document their dietary intake over this period.
400 ml of commercially-available nutritional supplement.
|
|
Experimentální: 2
these subjects will receive an enhanced protein supplement "milkshake" during their study.
Product 4808.
|
Subjects will eat prepared meals for 3 days prior to their study; or they will document their dietary intake over this period.
400 ml Forticare, to which has been added extra protein and the amino acid leucine.
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
Muscle fractional synthetic rate of growth.
Časové okno: one day.
|
one day.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Robert Wolfe, PhD, University of Arkansas
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .